Dee Lin, PharmD, MS

Recent Patterns of Relapse and Associated Costs in Schizophrenia Patients Initiating Atypical Antipsychotics

Rohan Mahabaleshwarkar , PhD;

Jesse Fishman , PharmD;

Timothy Hetherington , MS;

Constance Krull , MSPH;

Dee Lin , PharmD, MS;

Oleg Tcheremissine , MD;

11/22/2019

BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System

Aurélie Côté-Sergent , MSc;

11/22/2019

Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...

Rohan Mahabaleshwarkar , PhD;

Jesse Fishman , PharmD;

Todd Blair ;

Dee Lin , PharmD, MS;

Timothy Hetherington , MS;

Hospitalizations, Emergency Room Visits and Adherence Among Patients With Schizophrenia Initiated on Long-Acting Injectable Versus Oral Antipsychotics: A Systematic Review and Meta-Analysis

Pooja Palmer ;

Kruti Joshi , MPH, MD;

Constance Krull , MSPH;

Oleg Tcheremissine , MD;

10/08/2020

Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have the potential to increase medication adherence in adult patients with schizophrenia. This increas...

Philippe Thomas-Leduc , MSc;

Isabelle Ghelerter ;

Patrick Lefebvre , MA;

Ha Nguyen , BA;

Dee Lin , PharmD, MS;

Panagiotis Mavros , PhD;

Non-Healthcare Societal Burden of Schizophrenia Among Veterans

10/08/2020

Introduction: Schizophrenia (SCZ) is a severe mental disorder imposing substantial healthcare burden to society. Data quantifying the non-healthcare societal burden of SCZ is limited, esp...

Medication Adherence, Healthcare Resource Utilization, and Costs Among Medicaid Beneficiaries With Schizophrenia Treated With Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate

Hyunchung Kim ;

Maya Aboumrad , MPH;

Keiko Wada ;

Ethan Powell , BA;

Gabrielle Zwain , BA;

Aimee Near ;

Dee Lin , PharmD, MS;

10/08/2020

Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...

Maryia Zhdanava , MA;

Drivers of Prescribing Long-Acting Injectable Antipsychotics to Patients with Schizophrenia

Kruti Joshi , MPH, MD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Aurelie Cote ;

Maude Vermette-Laforme , BSc;

10/08/2020

Long-acting injectable (LAI) antipsychotics are recommended by clinical guidelines for patients with schizophrenia who struggle with adherence and/or recurrent relapses. However, LAI util...

Alexander Keenan , MA, MS, MD;

Dee Lin , PharmD, MS;

Jason Shepherd , BA;

Hollie Bailey , BSc;

Jack Wright ;

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

Katy Bacon ;

Edward S. Kim , MD, FACP, MBA;

10/08/2020

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Laura Morrison , MPH;

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

11/22/2019

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Maryia Zhdanava , MA;